<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-273" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vinca Alkaloid Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Richard J.</given-names>
          </name>
          <aff>Jefferson-Einstein Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Menezes</surname>
            <given-names>Ritesh G.</given-names>
          </name>
          <aff>College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Chen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ritesh Menezes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-273.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Vinca alkaloids, a cell cycle phase M-specific anti-tubulin agent class, have been pivotal in cancer treatment since their early development. Derived from the periwinkle plant (<italic toggle="yes">Catharanthus roseus</italic>), these alkaloids include first-generation (vincristine, vinblastine), second-generation semi-synthetic derivatives (vinorelbine, vindesine), and the latest addition, vinflunine&#x02014;known for fluorinated, anti-microtubule properties. Vinflunine stands out with enhanced potency and reduced adverse events, particularly in the context of treating transitional cell urothelial bladder cancer. These medications pose challenges, as toxicity spans multiple organ systems, predominantly manifesting as neurotoxicity, and necessitates vigilance in therapeutic dosing to avoid adverse events, especially with vincristine.</p>
        <p>Participants explore the spectrum of vinca alkaloid toxicity, focusing on early recognition and management of adverse effects. Updated insights into dose adjustments, patient-specific risk factors, and tailored interventions are discussed. The role of the interprofessional team, including oncologists, nurses, pharmacists, and therapists, in comprehensive patient care is emphasized. By fostering interdisciplinary collaboration, clinicians enhance patient safety through early detection, tailored interventions, and optimized treatment strategies. Engagement in this course empowers healthcare professionals to recognize and manage vinca alkaloid toxicity effectively. This course ensures clinicians are equipped with the latest knowledge and skills to navigate the complexities of vinca alkaloid therapy, ultimately improving patient care and outcomes in cancer treatment.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the signs and symptoms of vinca alkaloid toxicity in patients, including but not limited to neurotoxicity, gastrointestinal effects, and hematological abnormalities.</p></list-item><list-item><p>Differentiate between vinca alkaloid toxicity and other causes of toxicity to ensure timely intervention.</p></list-item><list-item><p>Assess the severity of vinca alkaloid toxicity through clinical evaluation, laboratory monitoring, and imaging studies&#x000a0;if needed.</p></list-item><list-item><p>Implement&#x000a0;interprofessional collaboration&#x000a0;to optimize the management of patients experiencing vinca alkaloid toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=273&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=273">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-273.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Vinca alkaloids, which belong to a class of cell cycle phase M-specific anti-tubulin agents, were one of the first plant alkaloids to be developed for use as anti-cancer agents in humans. Vinca alkaloids derived from&#x000a0;<italic toggle="yes">Vinca rosea</italic>&#x000a0;or the periwinkle plant (<italic toggle="yes">Catharanthus roseus</italic>) include first-generation (vincristine, vinblastine), second-generation semi-synthetic derivatives (vinorelbine, vindesine), and third-generation (vinflunine). Some have also classified vinflunine as a second-generation agent.<xref ref-type="bibr" rid="article-273.r1">[1]</xref>&#x000a0;Vinflunine is the newest vinca alkaloid and fluorinated anti-microtubule agent. The medication has been used to treat transitional cell urothelial bladder cancer. Vinflunine is reported to have a higher potency and lower frequency of adverse events when compared to the older vinca alkaloid agents.<xref ref-type="bibr" rid="article-273.r2">[2]</xref>&#x000a0;Vinca alkaloids are usually combined with other agents (as part of multi-drug combination regimens) since they potentiate the anti-cancer effects. These are also known to be well tolerated with manageable adverse events.<xref ref-type="bibr" rid="article-273.r3">[3]</xref>&#x000a0;</p>
        <p>Examples of multidrug regimens include:</p>
        <list list-type="bullet">
          <list-item>
            <p>CVP: cyclophosphamide, vincristine and prednisone</p>
          </list-item>
          <list-item>
            <p>CHOP: cyclophosphamide, doxorubicin, vincristine and prednisone</p>
          </list-item>
          <list-item>
            <p>VCRT: vinblastine, cisplatin, radiation therapy</p>
          </list-item>
          <list-item>
            <p>CISCA/VB: cisplatin, doxorubicin, cyclophosphamide, vinblastine and bleomycin</p>
          </list-item>
          <list-item>
            <p>ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine</p>
          </list-item>
        </list>
        <p>Toxicity from vinca alkaloids affects multiple organ systems, including the peripheral and central nervous, cardiovascular, hematologic, renal, and pulmonary systems. Neurotoxicity is the most commonly reported adverse event.</p>
      </sec>
      <sec id="article-273.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Vinca alkaloids function as microtubule inhibitors, inhibiting the polymerization of tubulin, which is necessary for spindle formation during the M-phase of the cell cycle.<xref ref-type="bibr" rid="article-273.r4">[4]</xref>&#x000a0;While they disrupt microtubular function at low doses, cell cycle arrest and apoptosis are seen at higher doses.<xref ref-type="bibr" rid="article-273.r5">[5]</xref>&#x000a0;Cell cycle arrest has been attributed to phosphorylation of the pro-apoptotic B-cell lymphoma (BCL-2) protein and increased levels of BCL&#x02013;2&#x02013;associated&#x000a0;X protein.<xref ref-type="bibr" rid="article-273.r6">[6]</xref>&#x000a0;Microtubules are also involved in other essential cell cycle functions, such as transcellular transport, cellular motility, and stability of the cellular cytoskeleton; hence, their effects are seen in other crucial cellular functions.<xref ref-type="bibr" rid="article-273.r7">[7]</xref>&#x000a0;Clinicians should avoid the concomitant use of these drugs with azole antifungals due to the increased risk of neurotoxicity, which has been known to present with seizures.<xref ref-type="bibr" rid="article-273.r8">[8]</xref>&#x000a0;This is due to the inhibition of cytochrome P450 3A4, leading to decreased metabolism, as well as inhibition of p-glycoprotein, which usually transports xenobiotics out of a cell.<xref ref-type="bibr" rid="article-273.r9">[9]</xref>&#x000a0;These mechanisms lead to increased serum concentrations of vinca alkaloids.</p>
      </sec>
      <sec id="article-273.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Toxicity, via therapeutic dosing and overdose, occurs for all vinca alkaloids. Acute toxicity due to overdose has been reportedly most frequently with vincristine, which can occur with administration through incorrect route, incorrect dosing, confusing vincristine with vinblastine, and confusing different strength vials. Neurotoxicity, specifically peripheral neuropathy, is one of the most commonly reported adverse events of vinca alkaloids, with vincristine implicated in the majority of cases. Risk factors include smoking, pre-existing neuropathy, renal dysfunction, higher dosing, and specific gene mutations.<xref ref-type="bibr" rid="article-273.r10">[10]</xref>&#x000a0;All vinca alkaloids are associated with the occurrence of the syndrome of inappropriate diuretic hormone (SIADH), with moderate to severe hyponatremia being reported in 11% for vincristine and higher for vinblastine. The onset of SIADH is variable and agent-dependent.<xref ref-type="bibr" rid="article-273.r11">[11]</xref>&#x000a0;</p>
        <p>
<bold>Vincristine</bold>
</p>
        <p>Vincristine is used to treat Philadelphia chromosome-negative acute lymphoblastic leukemia, B-cell lymphoma, estrogen-receptor-negative breast cancer, glioma, colorectal cancer, multiple myeloma, and Wilm tumor. Neurotoxicity is the most common adverse event from vincristine. Signs and symptoms are known to emerge within 1 week of initiation.<xref ref-type="bibr" rid="article-273.r12">[12]</xref>&#x000a0;The prevalence of vincristine-induced neuropathy is known to be 1.36% in younger populations and as high as 30% in the adult population.<xref ref-type="bibr" rid="article-273.r13">[13]</xref>&#x000a0;The presence of pre-existent diabetic neuropathy and Charcot-Marie-Tooth disease type I correlate with a higher risk of developing sensorimotor polyneuropathy. The incidence of neurotoxicity is more common in Black patients and those receiving higher doses of vincristine during treatment. Lower expression of cytochrome (CYP) CYP3A4 and CYP3A5, responsible for the metabolism of vincristine, is associated with an increased risk of peripheral neuropathy.<xref ref-type="bibr" rid="article-273.r9">[9]</xref><xref ref-type="bibr" rid="article-273.r14">[14]</xref><xref ref-type="bibr" rid="article-273.r15">[15]</xref>Central nervous system toxicity also occurs with greater severity than the other vinca alkaloids.</p>
        <p>
<bold>Vinblastine</bold>
</p>
        <p>Vinblastine is used to treat various liquid cancers, such as leukemia, Hodgkin and non-Hodgkin lymphoma, breast cancer, and testicular carcinoma. Paralytic ileus is more common when using vincristine. Research shows the condition occurs with a frequency of 2% to 4% in patients receiving vinblastine.<xref ref-type="bibr" rid="article-273.r16">[16]</xref>&#x000a0;Transient elevation of transaminases occurs in 5% to 10% of cases.<xref ref-type="bibr" rid="article-273.r17">[17]</xref>&#x000a0;Myelosuppression occurs with increased severity as compared with vincristine. The risk of febrile neutropenia is apparent in those receiving chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) scheduled for Hodgkin lymphoma to be less than 10% by the National Comprehensive Cancer Network guidelines, the incidence of grade III/IV neutropenia is said to have been 20.9%.<xref ref-type="bibr" rid="article-273.r18">[18]</xref></p>
        <p>
<bold>Vindesine</bold>
</p>
        <p>Vindesine has been used for treating pediatric solid tumors, blast-crisis, as well as breast, renal, and esophageal carcinomas. The severity of neurotoxicity is reported to be higher with vindesine as compared with vincristine. The dose-limiting effect is often myelosuppression, leading to leukopenia.<xref ref-type="bibr" rid="article-273.r19">[19]</xref></p>
        <p>
<bold>Vinorelbine</bold>
</p>
        <p>Vinorelbine is used for advanced breast cancer and advanced non-small cell lung cancer. Vinorelbine is associated with mild to moderate neuropathy and constipation. Further, mild to moderate nausea and vomiting occur in a third of patients on vinorelbine, whereas diarrhea and stomatitis are less frequent.<xref ref-type="bibr" rid="article-273.r20">[20]</xref>&#x000a0;</p>
        <p>
<bold>Vinflunine</bold>
</p>
        <p>Vinflunine is a derivative of vinorelbine, used for the treatment of bladder cancer that has failed platinum-based treatment. In the CURVE trial, adverse events included anemia, neutropenic fever, fatigue, and constipation. Peripheral neuropathy is reported but had occurred similarly to the control group.<xref ref-type="bibr" rid="article-273.r21">[21]</xref></p>
      </sec>
      <sec id="article-273.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The microtubular apparatus plays a pivotal role in axonal transport and secretory function. The normal function of the microtubule apparatus involves polymerization and depolymerization of individual &#x003b1; and &#x003b2; subunits. Vinca alkaloids bind to specific sites on the &#x003b2;-subunit and prevent propagation of the microtubule. The inhibitory action of these drugs on the microtubular apparatus is responsible for their anti-cancer effects and toxicity. Vinca alkaloids penetrate the blood-brain barrier poorly due to their large size and significant protein binding. As a result, effects on the peripheral nervous system predominate over central nervous system actions.<xref ref-type="bibr" rid="article-273.r22">[22]</xref></p>
        <p>Overproduction of P-glycoprotein by cancer cells may lead to resistance to various anti-cancer drugs, including vinca alkaloids.<xref ref-type="bibr" rid="article-273.r23">[23]</xref>&#x000a0;Mutations in &#x003b2;-tubulin with overexpression of different isotypes may also correlate with the production of altered effects, leading to developing drug resistance.<xref ref-type="bibr" rid="article-273.r24">[24]</xref></p>
      </sec>
      <sec id="article-273.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Current data suggest that vinca alkaloids exhibit a triphasic clearance. The initial 2 phases are similar for all agents, with rapid distribution and uptake into peripheral tissues. The terminal phase depends on the agent in question, as this phase is dependent on tissue sequestration. All vinca alkaloids bind plasma proteins. Distribution into peripheral tissues also depends on the contained cells' tubulin content.<xref ref-type="bibr" rid="article-273.r25">[25]</xref>&#x000a0;All vinca alkaloids are metabolized by the CYP3A isozyme and undergo majority hepatobiliary elimination with almost no renal clearance.<xref ref-type="bibr" rid="article-273.r26">[26]</xref>&#x000a0;</p>
        <p>Capping the single maximum dose to 2 mg, irrespective of the body surface area, has been suggested to minimize the probability of occurrence of acute neurotoxicity.<xref ref-type="bibr" rid="article-273.r16">[16]</xref>&#x000a0;The use of vincristine mini bags is an alternative to prevent inadvertent intrathecal administration, which can be potentially lethal.<xref ref-type="bibr" rid="article-273.r27">[27]</xref>&#x000a0;Developing liposomal formulations may allow for more than the single recommended dose of 2 mg.<xref ref-type="bibr" rid="article-273.r28">[28]</xref></p>
      </sec>
      <sec id="article-273.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>When evaluating a patient with vinca alkaloid toxicity, obtain historical information concerning the patient's medical history, cancer history, and current chemotherapy regimen. Also, information concerning the patient's most recent treatment, the amount, and the route of administration must be obtained. Questions should be directed to help determine the organ systems involved, the onset time, and the severity of symptoms.</p>
        <p>
<bold>Peripheral Nervous System</bold>
</p>
        <p>The incidence of peripheral neuropathy, which presents in a typical glove and stocking distribution and proceeds from a distal to a proximal fashion with vincristine, is known to range between 35% and 45%.<xref ref-type="bibr" rid="article-273.r29">[29]</xref>&#x000a0;Vincristine-induced neurotoxicity is known to present with sensory, motor, and autonomic symptoms. Dose-limiting toxicity of vincristine, predominantly sensory, presents with painful dysesthesias, ataxia, foot drop, and cranial nerve palsy (affecting extraocular and laryngeal muscles). Neurotoxicity is dose-dependent, with a 2 to 6 mg dose threshold for developing sensory symptoms. Guidelines suggest a single dose of vincristine should not exceed 2 mg to prevent neurotoxicity. Peripheral neurotoxicity may present with areflexia as the initial complaint, followed by paraesthesias. Muscle cramps herald the onset of sensory symptoms.<xref ref-type="bibr" rid="article-273.r30">[30]</xref>&#x000a0;While the sensory deficit may be reversible, the motor symptoms are known to be irreversible. Posterior column involvement with the loss of joint position sense is an indication to stop using these drugs. Vincristine is associated with acute motor axonal neuropathy development, which must be distinguished from other forms of Guillain-Barre syndrome, particularly acute inflammatory demyelinating polyneuropathy.<xref ref-type="bibr" rid="article-273.r31">[31]</xref>&#x000a0;A severe peripheral neuropathy presenting with quadriparesis has also been reported with vincristine in patients with Guillain-Barre syndrome.<xref ref-type="bibr" rid="article-273.r12">[12]</xref>&#x000a0;The family history of Charcot-Marie-Tooth disease is a contraindication to the use of vincristine. Patients who develop signs of acute neurotoxicity with vincristine should undergo evaluation for this degenerative condition.<xref ref-type="bibr" rid="article-273.r32">[32]</xref>&#x000a0;The worsening of neuropathy symptoms upon cessation of chemotherapy, known as "coasting," is seen in 30% of patients.<xref ref-type="bibr" rid="article-273.r13">[13]</xref></p>
        <p>Autonomic neuropathy, which presents with constipation, ileus, and abdominal cramps, may require pre-emptive laxatives.<xref ref-type="bibr" rid="article-273.r33">[33]</xref>&#x000a0;Autonomic symptoms may also lead to bladder atony, which manifests as urinary retention, polyuria, and dysuria.<xref ref-type="bibr" rid="article-273.r34">[34]</xref>&#x000a0;Autonomic effects on the cardiovascular system may present as arterial hypertension or hypotension and orthostatic hypotension.<xref ref-type="bibr" rid="article-273.r35">[35]</xref>&#x000a0;The onset of mild autonomic symptoms is known to predate the development of peripheral neuropathy.<xref ref-type="bibr" rid="article-273.r36">[36]</xref>&#x000a0;Capping the single maximum dose of vincristine to 2 mg, irrespective of the body surface area, has been suggested as an option to minimize the probability of acute neurotoxicity occurrence.<xref ref-type="bibr" rid="article-273.r16">[16]</xref>&#x000a0;Using vincristine mini bags is an alternative to prevent inadvertent intrathecal administration, which can be potentially lethal.<xref ref-type="bibr" rid="article-273.r27">[27]</xref></p>
        <p>
<bold>Central Nervous System</bold>
</p>
        <p>Acute or subacute encephalopathy, seizures, and visual loss can occur when administering these drugs, typically in the setting of overdose or delayed elimination.<xref ref-type="bibr" rid="article-273.r37">[37]</xref>&#x000a0;Other less frequent side effects include transient cortical blindness with posterior reversible encephalopathy syndrome, unilateral or bilateral optic neuropathy, ataxia, visual hallucinations, tremors, parkinsonism, and syndrome of inappropriate antidiuretic hormone secretion.<xref ref-type="bibr" rid="article-273.r38">[38]</xref>&#x000a0;The latter is more common in patients receiving intravenous hydration and may present with encephalopathy and generalized seizures.<xref ref-type="bibr" rid="article-273.r39">[39]</xref>&#x000a0;Accidental intrathecal administration is associated with ascending myelopathy, coma, and death.<xref ref-type="bibr" rid="article-273.r40">[40]</xref></p>
        <p>Jaw pain with a neuropathic component, which is non-responsive to traditional pain medications, has been reported with the use of vincristine. A hypothesis exists that this pain results from the fifth cranial nerve (trigeminal nerve) involvement.<xref ref-type="bibr" rid="article-273.r36">[36]</xref>&#x000a0;Vincristine-induced vocal cord palsy, which is a potentially reversible phenomenon and subsides with the cessation of the drug, has also been reported in the literature.<xref ref-type="bibr" rid="article-273.r41">[41]</xref>&#x000a0;The involvement of the vocal cords, which presents with hoarseness of voice, could present as unilateral or bilateral but has been reported to be more common on the left side. While bilateral involvement is known to localize to the vagal nucleus neurologically, unilateral involvement is known to occur due to recurrent laryngeal nerve involvement.<xref ref-type="bibr" rid="article-273.r42">[42]</xref>&#x000a0;Higher doses, preexisting hepatic dysfunction, neuropathic illness, history of hypersensitivity to the drug, and co-administration of other cancer chemotherapy agents and non-chemotherapy drugs such as mitomycin&#x02013;C, allopurinol, azathioprine, phenytoin, isoniazid, and itraconazole has also shown a predisposition to an increased risk of vocal cord palsy.<xref ref-type="bibr" rid="article-273.r43">[43]</xref>&#x000a0;Seizures, as a direct effect, can occur in severe toxicity, particularly in acute overdoses.<xref ref-type="bibr" rid="article-273.r44">[44]</xref></p>
        <p>
<bold>Hematological Toxicity</bold>
</p>
        <p>Vincristine is usually a bone marrow-sparing agent. Reports exist of dose-limiting hematological toxicity of vinblastine.<xref ref-type="bibr" rid="article-273.r45">[45]</xref>&#x000a0;Leukopenia is more common than thrombocytopenia, and anemia is not as common. Vinorelbine and vindesine are also known to cause bone marrow toxicity.<xref ref-type="bibr" rid="article-273.r46">[46]</xref></p>
        <p>
<bold>Renal Toxicity</bold>
</p>
        <p>Vinblastine and its active metabolite desacetylvinblastine, vincristine, and vindesine have low renal excretion (10% to 15%).<xref ref-type="bibr" rid="article-273.r3">[3]</xref>&#x000a0;No dose adjustment has been advised for vinca alkaloids as a class. However, the dose of vinorelbine should be reduced by 50% in patients undergoing hemodialysis due to an increased risk of adverse events.<xref ref-type="bibr" rid="article-273.r47">[47]</xref></p>
        <p>
<bold>Hepatic Toxicity</bold>
</p>
        <p>Since vincristine is primarily metabolized in the liver, dose adjustments are recommended for hepatic dysfunction with hyperbilirubinemia, particularly in cases with an elevation of the direct bilirubin fraction.<xref ref-type="bibr" rid="article-273.r17">[17]</xref>&#x000a0;Both vincristine and vinblastine are known to cause hepatic sinusoidal obstruction syndrome (hepatic veno-occlusive disease) in children or predisposed individuals, namely those with higher doses of radiation and concurrent use of dactinomycin and cyclophosphamide.<xref ref-type="bibr" rid="article-273.r48">[48]</xref><xref ref-type="bibr" rid="article-273.r49">[49]</xref>&#x000a0;The adverse events include jaundice, anasarca, weight gain, and right upper quadrant pain.</p>
        <p>
<bold>Pulmonary Toxicity</bold>
</p>
        <p>Acute dyspnea and bronchospasm may occur with the concurrent use of vincristine and vinblastine with mitomycin-C.<xref ref-type="bibr" rid="article-273.r50">[50]</xref></p>
        <p>
<bold>Gastrointestinal Toxicity</bold>
</p>
        <p>Vinca alkaloids are associated with the development of oral-mucosal ulcerations and paralytic ileus. Vinorelbine and its metabolites are associated with chemotherapy-induced autonomic neuropathy, which may present with constipation and urinary retention through activation of the muscarinic receptors.<xref ref-type="bibr" rid="article-273.r51">[51]</xref>&#x000a0;</p>
        <p>
<bold>Cardiovascular Toxicity</bold>
</p>
        <p>Apart from the cardiovascular autonomic effects, which present as disturbances in the hemodynamic parameters (eg, hypotension, tachycardia), these drugs have also correlated with cardiac ischemic pain presenting with electrocardiographic abnormalities and myocardial infarction.<xref ref-type="bibr" rid="article-273.r52">[52]</xref></p>
        <p>
<bold>Local Effects</bold>
</p>
        <p>Vincristine and vinblastine are known to act as vesicants and cause chemotherapy-associated extravasation.<xref ref-type="bibr" rid="article-273.r53">[53]</xref>&#x000a0;Recommendations include caution against the intramuscular, subcutaneous, and intraperitoneal use of vinca alkaloids. A bolus injection is recommended whenever possible due to the risks associated with local administration. Local reactions related to the injection include erythema, pain, and discoloration.<xref ref-type="bibr" rid="article-273.r54">[54]</xref></p>
        <p>
<bold>Other Rare Adverse Events</bold>
</p>
        <p>Alopecia is a rare adverse event of these drugs.<xref ref-type="bibr" rid="article-273.r55">[55]</xref></p>
      </sec>
      <sec id="article-273.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Testing should be directed at evaluating for end-organ toxicity. A complete blood count, basic metabolic panel, liver function tests, and coagulation panel should be obtained to assess leukopenia, anemia and thrombocytopenia, electrolyte abnormalities and kidney function, liver dysfunction, and coagulopathy. An electrocardiogram and troponin testing should be performed if a concern for myocardial ischemia is apparent. Although generally not readily available, vinca alkaloids can be obtained. Testing of bodily fluids such as blood and cerebral spinal fluid can be used as a potential prognostication tool, as higher levels are associated with more severe toxicity. Advanced imaging should be used to explore other potential differentials.</p>
        <p>Syndrome of inappropriate antidiuretic hormone is known to be present with symptoms of hypovolemic hyponatremia and may require determination of urine and plasma osmolarity for diagnosis. Hepatic venous-occlusive disease is associated with decreased or absent blood flow in the hepatic vein on duplex ultrasonography. Liver function tests are usually abnormal. The Seattle and Baltimore criteria have been useful in diagnosing hepatic veno-occlusive disease. Hyperbilirubinemia with a serum bilirubin level exceeding 2 mg/dL has been positioned as the sine qua non in the diagnosis. In contrast, transfusion refractory thrombocytopenia is an addition to a recent modification of the diagnostic criteria.<xref ref-type="bibr" rid="article-273.r56">[56]</xref></p>
        <p>Various tools are used to evaluate chemotherapy-induced peripheral neuropathy, namely the "Common Terminology Criteria for Adverse Events" developed by the National Cancer Institute, the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire C30, and the Chemotherapy-Induced Peripheral Neuropathy-20 Questionnaire.<xref ref-type="bibr" rid="article-273.r57">[57]</xref><xref ref-type="bibr" rid="article-273.r58">[58]</xref><xref ref-type="bibr" rid="article-273.r59">[59]</xref><xref ref-type="bibr" rid="article-273.r60">[60]</xref><xref ref-type="bibr" rid="article-273.r61">[61]</xref>&#x000a0;No tools specific for neurotoxicity caused by vinca alkaloids exist, although various risk factors predisposing to neurotoxic adverse events are identified.</p>
        <p>Both nerve conduction studies and electromyography are expected to demonstrate symptoms of axonopathy, but they are not routinely performed due to the costs involved. An indirect laryngoscopic examination in patients with hoarseness of voice will likely demonstrate reduced mobility of the affected vocal cord.&#x000a0;</p>
      </sec>
      <sec id="article-273.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Fluid restriction, supplementation with 3% hypertonic saline, and use of loop diuretics are the recommendations for managing syndrome of inappropriate antidiuretic hormone.<xref ref-type="bibr" rid="article-273.r39">[39]</xref>&#x000a0;Neutropenia can be treated with a granulocyte colony-stimulating factor.<xref ref-type="bibr" rid="article-273.r62">[62]</xref>&#x000a0;Seizures are treated primarily with benzodiazepines. Regular surveillance and patient education strategies are necessary to recognize neurological symptomatic adverse events early. Modification of the administered dose, use of alternative treatment (substitution of vincristine with vindesine is advisable in patients with Charcot-Marie-Tooth disease), and cessation of chemotherapy in case of severe, life-threatening toxicities seem to be the most effective strategies to control the adverse effects.<xref ref-type="bibr" rid="article-273.r63">[63]</xref>&#x000a0;</p>
        <p>While researchers have studied many neuroprotective and neurostimulatory strategies, more robust scientific evidence is needed to support their use. Both pyridostigmine and pyridoxine improve the rate of recovery of vincristine-induced peripheral neuropathy. In contrast, the role of glutamic acid in treating this condition has been a subject of pre-clinical studies.<xref ref-type="bibr" rid="article-273.r16">[16]</xref><xref ref-type="bibr" rid="article-273.r64">[64]</xref>&#x000a0;A double-blind, randomized control trial to assess the efficacy of glutamic acid in the prevention of vincristine-induced neurotoxicity reportedly showed a negative outcome.<xref ref-type="bibr" rid="article-273.r65">[65]</xref>&#x000a0;About 55% to 66% of pediatric patients presenting with vincristine-induced bilateral vocal cord palsy may need airway protection and, in severe cases, tracheostomy.<xref ref-type="bibr" rid="article-273.r42">[42]</xref></p>
        <p>Secondary preventive strategies to mitigate the impact of these adverse effects on the patient's quality of life can be beneficial. Patient and caregiver education, lifestyle interventions, physical and occupational therapy approaches, and avoiding risk factors predisposing to a neurological insult can also improve outcomes.<xref ref-type="bibr" rid="article-273.r66">[66]</xref>&#x000a0;The risk of long-term neurotoxicity should be recognized, and rehabilitative approaches should mitigate the impact of this neurological insult on the patient's quality of life.<xref ref-type="bibr" rid="article-273.r12">[12]</xref>&#x000a0;Physical therapy can provide benefits for the amelioration of motor symptoms.<xref ref-type="bibr" rid="article-273.r67">[67]</xref>&#x000a0;Defibrotide is a viable treatment option in the management of hepatic veno-occlusive disease.<xref ref-type="bibr" rid="article-273.r68">[68]</xref>&#x000a0;Surgical, interventional radiology, and hepatic consultation should be obtained to assist with management.</p>
        <p>Flushing the veins after injection is advisable to minimize inflammation. Extravasations of vinca alkaloids have shown an association with skin ulceration up to 24 hours after administering these agents, for which hyaluronidase and corticosteroids can provide viable treatment options. Urgent surgical consultation and immediate debridement are necessary for severe cases.<xref ref-type="bibr" rid="article-273.r69">[69]</xref><xref ref-type="bibr" rid="article-273.r70">[70]</xref>&#x000a0;Intrathecal administration of vinca alkaloids is a neurosurgical emergency, and prompt neurosurgical consultation may limit morbidity and mortality. Cerebral spinal fluid aspiration, irrigation, and intrathecally administrating folinic acid, glutamic acid, and pyridoxine have been reported with variable results.<xref ref-type="bibr" rid="article-273.r71">[71]</xref><xref ref-type="bibr" rid="article-273.r72">[72]</xref><xref ref-type="bibr" rid="article-273.r73">[73]</xref></p>
        <p>Extracorporeal removal should be considered in patients with severe toxicity. Due to rapid distribution and high protein binding, other methods than hemodialysis may be beneficial. Plasmapheresis in adults and exchange transfusion in children successfully decrease serum concentrations of vincristine.<xref ref-type="bibr" rid="article-273.r74">[74]</xref><xref ref-type="bibr" rid="article-273.r75">[75]</xref></p>
      </sec>
      <sec id="article-273.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Peripheral neuropathy can occur due to various etiologies, but historical information about current treatment helps narrow a diagnosis. Peripheral neuropathy is associated with other anti-cancer medications, such as epothilones (ixabepilone), taxanes (paclitaxel, docetaxel), and platinum-based antineoplastics (oxaliplatin and cisplatin). The differential for syndrome of inappropriate antidiuretic hormone includes neoplasm (eg, small cell lung carcinoma), central nervous system pathology (eg, stroke, hemorrhage), and drug-associated (eg, carbamazepine, selective serotonin reuptake inhibitors).<xref ref-type="bibr" rid="article-273.r76">[76]</xref><xref ref-type="bibr" rid="article-273.r77">[77]</xref>&#x000a0;Electrolyte abnormalities (hypokalemia), reduced oral intake, opioid-induced constipation, and peritoneal carcinomatosis may be considered in the differential diagnosis for constipation or ileus.<xref ref-type="bibr" rid="article-273.r78">[78]</xref></p>
      </sec>
      <sec id="article-273.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>Randomized clinical trials examining the effect of putative neuroprotective agents such as glutamine, acetyl-L-carnitine, and vitamins B12 and B6 against vincristine-induced neuropathy have been performed. Glutamine was studied in the pediatric and adolescent population and was associated with improved sensory function and reported quality of life.<xref ref-type="bibr" rid="article-273.r79">[79]</xref>&#x000a0;In a pilot study of Chinese patients with cancer, acetyl-L-carnitine was associated with improved sensory function and decreased fatigue.<xref ref-type="bibr" rid="article-273.r80">[80]</xref>&#x000a0;Another study looked at vitamins B12 and B6 to prevent peripheral neuropathy in neurotoxic chemotherapy agents and found no difference in the prevention of neuropathy compared to controls, but decreased severity was a potential benefit.<xref ref-type="bibr" rid="article-273.r81">[81]</xref></p>
      </sec>
      <sec id="article-273.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Acute toxicity effects, such as gastrointestinal distress, hematologic toxicity, or cardiovascular effects, may last several days after discontinuation of the vinca alkaloid and depend on rapid identification. Mild symptoms of vincristine-induced peripheral neuropathy generally subside over weeks to months with no residual deficits. Severe symptoms may persist for months to years without complete resolution. Vincristine-induced vocal cord palsy is generally reversible, with complete recovery expected within 6 to 9 months.<xref ref-type="bibr" rid="article-273.r42">[42]</xref></p>
      </sec>
      <sec id="article-273.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Long-term sequelae of neuropathy have been reported in patients many years after cessation of treatment with vincristine, and a negative impact on the quality of life adds to the long-lasting morbidity.<xref ref-type="bibr" rid="article-273.r16">[16]</xref></p>
      </sec>
      <sec id="article-273.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Vinca alkaloid chemotherapeutic agents are associated with significant toxicity. As a patient,&#x000a0;reporting adverse effects during cancer treatment is important. Early identification of symptoms is crucial to reduce the potential impact on quality of life and prevent worsening symptoms. Delayed&#x000a0;diagnosis may lead to electrolyte derangements, hepatotoxicity, severe infection, seizures, and&#x000a0;peripheral neuropathy.</p>
      </sec>
      <sec id="article-273.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Vinca alkaloids, commonly used in cancer treatment, pose a risk of toxicity that clinicians must be vigilant about. These chemotherapeutic agents, including vincristine and vinblastine, can lead to severe neurotoxicity if not carefully administered. Recognizing early signs such as neuropathic pain, muscle weakness, and constipation is crucial. Dose adjustment and careful administration via central venous access can help mitigate toxicity risks. Regular neurological assessments and close monitoring of patients during and after infusion are essential to identify and manage potential complications promptly. Clinicians should also be aware of drug interactions and adjust treatment plans accordingly. Through heightened awareness, meticulous administration, and proactive management, healthcare providers can optimize the benefits of Vinca alkaloids while minimizing the risk of toxicities, ensuring safer and more effective cancer therapy.</p>
        <p>Apart from the oncologist, the care team comprising nurses, nurse practitioners, physician assistants, pharmacists, technologists, physical and occupational therapists, and other physicians may also play a direct or indirect role in the treatment process. Therefore, monitoring patients for adverse effects is imperative. This can help minimize the morbidity and mortality resulting from vinca alkaloid treatment. The occurrence of neurotoxicity and extravasation should be anticipated in the acute setting. If an adverse effect is identified, the care team must work together to modify the treatment plan or institute appropriate treatment.</p>
      </sec>
      <sec id="article-273.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=273&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=273">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/vinca-alkaloid-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=273">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/273/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=273">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-273.s17">
        <title>References</title>
        <ref id="article-273.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Know the Medicinal Herb: Catharanthus roseus (Vinca rosea).</article-title>
            <source>Malays Fam Physician</source>
            <year>2008</year>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <pub-id pub-id-type="pmid">25606134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerullis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wawroschek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hne</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Ecke</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.</article-title>
            <source>Ther Adv Urol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-35</page-range>
            <pub-id pub-id-type="pmid">28042310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Drug delivery systems and combination therapy by using vinca alkaloids.</article-title>
            <source>Curr Top Med Chem</source>
            <year>2015</year>
            <volume>15</volume>
            <issue>15</issue>
            <fpage>1491</fpage>
            <page-range>1491-500</page-range>
            <pub-id pub-id-type="pmid">25877096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Cesare</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Verrico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giubettini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rovella</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coluccia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Famiglini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>La Regina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cundari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lavia</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules.</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <month>Mar</month>
            <day>21</day>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>19738</fpage>
            <page-range>19738-19759</page-range>
            <pub-id pub-id-type="pmid">28160569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bates</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eastman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Microtubule destabilising agents: far more than just antimitotic anticancer drugs.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-268</page-range>
            <pub-id pub-id-type="pmid">27620987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janumyan</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Sansam</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Chattopadhyay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Soucie</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Penn</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Knudson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry.</article-title>
            <source>EMBO J</source>
            <year>2003</year>
            <month>Oct</month>
            <day>15</day>
            <volume>22</volume>
            <issue>20</issue>
            <fpage>5459</fpage>
            <page-range>5459-70</page-range>
            <pub-id pub-id-type="pmid">14532118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fletcher</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Cell mechanics and the cytoskeleton.</article-title>
            <source>Nature</source>
            <year>2010</year>
            <month>Jan</month>
            <day>28</day>
            <volume>463</volume>
            <issue>7280</issue>
            <fpage>485</fpage>
            <page-range>485-92</page-range>
            <pub-id pub-id-type="pmid">20110992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pana</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Roilides</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2011</year>
            <month>Jul</month>
            <day>15</day>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-5</page-range>
            <pub-id pub-id-type="pmid">21265011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moriyama</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Henning</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Falade-Nwulia</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jarosinski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Penzak</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.</article-title>
            <source>Mycoses</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>290</fpage>
            <page-range>290-7</page-range>
            <pub-id pub-id-type="pmid">22126626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seretny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Currie</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Sena</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Ramnarine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>MacLeod</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.</article-title>
            <source>Pain</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>155</volume>
            <issue>12</issue>
            <fpage>2461</fpage>
            <page-range>2461-2470</page-range>
            <pub-id pub-id-type="pmid">25261162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verzicco</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Regolisti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Quaini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bocchi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brusasco</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Passeri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cannone</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Coghi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fiaccadori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vignali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Volpi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cabassi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Electrolyte Disorders Induced by Antineoplastic Drugs.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>779</fpage>
            <pub-id pub-id-type="pmid">32509580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mora</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Donohoe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Vincristine-induced peripheral neuropathy in pediatric cancer patients.</article-title>
            <source>Am J Cancer Res</source>
            <year>2016</year>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>2416</fpage>
            <page-range>2416-2430</page-range>
            <pub-id pub-id-type="pmid">27904761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staff</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Windebank</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-induced peripheral neuropathy: A current review.</article-title>
            <source>Ann Neurol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>81</volume>
            <issue>6</issue>
            <fpage>772</fpage>
            <page-range>772-781</page-range>
            <pub-id pub-id-type="pmid">28486769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aminkeng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Rassekh</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Brunham</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Sistonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dube</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nyambo</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Omar</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Froment</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bodo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tishkoff</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carleton</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>MR</given-names>
              </name>
              <collab>Canadian Pharmacogenomics Network for Drug Safety Consortium</collab>
            </person-group>
            <article-title>Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.</article-title>
            <source>Pharmacogenomics J</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-70</page-range>
            <pub-id pub-id-type="pmid">23588107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skiles</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Olbara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Vik</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Mostert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abbink</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kaspers</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Njuguna</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sajdyk</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Renbarger</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>65</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29115708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madsen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Due</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ejskj&#x000e6;r</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dybk&#x000e6;r</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>471</fpage>
            <page-range>471-485</page-range>
            <pub-id pub-id-type="pmid">31214762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grigorian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity Secondary to Chemotherapy.</article-title>
            <source>J Clin Transl Hepatol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-102</page-range>
            <pub-id pub-id-type="pmid">26357620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vakkalanka</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma.</article-title>
            <source>Adv Hematol</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>656013</fpage>
            <pub-id pub-id-type="pmid">21687649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vats</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ragab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hvizdale</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nitschke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beardsley</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Maybee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Krischer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse. A Pediatric Oncology Group study.</article-title>
            <source>Invest New Drugs</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-4</page-range>
            <pub-id pub-id-type="pmid">1428733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hess</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Th&#x000fc;rlimann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Aebi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rauch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ballabeni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rufener</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Castiglione-Gertsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldhirsch</surname>
                <given-names>A</given-names>
              </name>
              <collab>Swiss Group of Clinical Cancer Research (SAKK)</collab>
            </person-group>
            <article-title>Capecitabine and vinorelbine in elderly patients (&#x0003e; or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).</article-title>
            <source>Ann Oncol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>1760</fpage>
            <page-range>1760-5</page-range>
            <pub-id pub-id-type="pmid">15550580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Th&#x000e9;odore</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Demkov</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Komyakov</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sengelov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daugaard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Caty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carles</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jagiello-Gruszfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karyakin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Delgado</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Hurteloup</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Winquist</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morsli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Salhi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Culine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>von der Maase</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Sep</month>
            <day>20</day>
            <volume>27</volume>
            <issue>27</issue>
            <fpage>4454</fpage>
            <page-range>4454-61</page-range>
            <pub-id pub-id-type="pmid">19687335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LaPointe</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Morfini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Feinstein</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy.</article-title>
            <source>Neurotoxicology</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>37</volume>
            <fpage>231</fpage>
            <page-range>231-9</page-range>
            <pub-id pub-id-type="pmid">23711742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robey</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pluchino</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Fojo</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gottesman</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the role of ABC transporters in multidrug-resistant cancer.</article-title>
            <source>Nat Rev Cancer</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>452</fpage>
            <page-range>452-464</page-range>
            <pub-id pub-id-type="pmid">29643473</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huzil</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurgan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tuszynski</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.</article-title>
            <source>Cancer Inform</source>
            <year>2007</year>
            <month>Apr</month>
            <day>27</day>
            <volume>3</volume>
            <fpage>159</fpage>
            <page-range>159-81</page-range>
            <pub-id pub-id-type="pmid">19455242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Theologides</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells.</article-title>
            <source>Cancer Res</source>
            <year>1980</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8 Pt 1</issue>
            <fpage>2695</fpage>
            <page-range>2695-700</page-range>
            <pub-id pub-id-type="pmid">6248211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Casamassima</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Castiglione</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cellupica</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pantalone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papagni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siciliano</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Collina</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.</article-title>
            <source>Bioorg Med Chem Lett</source>
            <year>2018</year>
            <month>Sep</month>
            <day>15</day>
            <volume>28</volume>
            <issue>17</issue>
            <fpage>2816</fpage>
            <page-range>2816-2826</page-range>
            <pub-id pub-id-type="pmid">30122223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nurgat</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Smythe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Jedai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ewing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rasheed</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Belgaumi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Ashour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al Agil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aljurf</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Introduction of vincristine mini-bags and an assessment of the subsequent risk of extravasation.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>339</fpage>
            <page-range>339-47</page-range>
            <pub-id pub-id-type="pmid">24821691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Development of a stable single-vial liposomal formulation for vincristine.</article-title>
            <source>Int J Nanomedicine</source>
            <year>2019</year>
            <volume>14</volume>
            <fpage>4461</fpage>
            <page-range>4461-4474</page-range>
            <pub-id pub-id-type="pmid">31296986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchettini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lacerenza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mauri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marangoni</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Painful peripheral neuropathies.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>175</fpage>
            <page-range>175-81</page-range>
            <pub-id pub-id-type="pmid">18615140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barron</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Muscle cramps associated with vincristine therapy.</article-title>
            <source>Acta Oncol</source>
            <year>1991</year>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>707</fpage>
            <page-range>707-11</page-range>
            <pub-id pub-id-type="pmid">1659838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Balter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marradi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferlisi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaccaron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiaschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Frasson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bertolasi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia.</article-title>
            <source>J Child Neurol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>867</fpage>
            <page-range>867-74</page-range>
            <pub-id pub-id-type="pmid">22241706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chauvenet</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Shashi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Selsky</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kurtzberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>B</given-names>
              </name>
              <collab>Pediatric Oncology Group Study</collab>
            </person-group>
            <article-title>Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>316</fpage>
            <page-range>316-20</page-range>
            <pub-id pub-id-type="pmid">12679647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McQuade</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Stojanovska</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Abalo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bornstein</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Nurgali</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.</article-title>
            <source>Front Pharmacol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>414</fpage>
            <pub-id pub-id-type="pmid">27857691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dewan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chhonker</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Vincristine induced neurotoxicity in cancer patients.</article-title>
            <source>Indian J Pediatr</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-100</page-range>
            <pub-id pub-id-type="pmid">19936661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adams</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Schondorf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benoit</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kilgour</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study.</article-title>
            <source>BMC Cancer</source>
            <year>2015</year>
            <month>May</month>
            <day>18</day>
            <volume>15</volume>
            <fpage>414</fpage>
            <pub-id pub-id-type="pmid">25981952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Talebian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goudarzi</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Mohammadzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirzadeh</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Vincristine-induced cranial neuropathy.</article-title>
            <source>Iran J Child Neurol</source>
            <year>2014</year>
            <season>Winter</season>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-8</page-range>
            <pub-id pub-id-type="pmid">24665331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Cancer-treatment-induced neurotoxicity--focus on newer treatments.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-105</page-range>
            <pub-id pub-id-type="pmid">26391778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magge</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>The double-edged sword: Neurotoxicity of chemotherapy.</article-title>
            <source>Blood Rev</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-100</page-range>
            <pub-id pub-id-type="pmid">25445718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagappa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sudeep</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Badhe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hemavathi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Vincristine-induced acute life-threatening hyponatremia resulting in seizure and coma.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2009</year>
            <season>Jul-Sep</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-8</page-range>
            <pub-id pub-id-type="pmid">20040817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grissinger</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Death and Neurological Devastation From Intrathecal Vinca Alkaloids.</article-title>
            <source>P T</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>464</fpage>
            <page-range>464-525</page-range>
            <pub-id pub-id-type="pmid">27504060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patra</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Mandal</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Phukan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jitani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Vincristine Induced Reversible Vocal Cord Palsy in a Young Adult.</article-title>
            <source>Indian J Hematol Blood Transfus</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>182</fpage>
            <page-range>182-183</page-range>
            <pub-id pub-id-type="pmid">30828171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samoon</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shabbir-Moosajee</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vincristine-induced vocal cord palsy and successful re-treatment in a patient with diffuse large B cell lymphoma: a case report.</article-title>
            <source>BMC Res Notes</source>
            <year>2014</year>
            <month>May</month>
            <day>27</day>
            <volume>7</volume>
            <fpage>318</fpage>
            <pub-id pub-id-type="pmid">24886197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farruggia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tropia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cannella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bruno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oddo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Vocal cord palsy after vincristine treatment in a child and the inefficacy of glutamic acid in the prevention of relapse: a case report.</article-title>
            <source>J Med Case Rep</source>
            <year>2012</year>
            <month>May</month>
            <day>14</day>
            <volume>6</volume>
            <fpage>128</fpage>
            <pub-id pub-id-type="pmid">22584039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Panahishokouh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Babakhani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aghabeigi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vaezi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hadjibabaie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shahrami</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Vincristine-Induced Seizure from Drug Interactions: A Case Report and Review of Literature.</article-title>
            <source>Case Rep Oncol</source>
            <year>2023</year>
            <season>Jan-Dec</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>363</fpage>
            <page-range>363-371</page-range>
            <pub-id pub-id-type="pmid">37384200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bordbar</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bazrafshan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Successful Management of Vinblastin Overdose with Exchange Transfusion: A Case Report.</article-title>
            <source>Iran J Ped Hematol Oncol</source>
            <year>2015</year>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-5</page-range>
            <pub-id pub-id-type="pmid">26131351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bombery</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors.</article-title>
            <source>Transfusion</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>54</volume>
            <issue>8</issue>
            <fpage>2004</fpage>
            <page-range>2004-14</page-range>
            <pub-id pub-id-type="pmid">24527786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Launay-Vacher</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Oudard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Janus</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gligorov</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pourrat</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Rixe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Morere</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Beuzeboc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
              <collab>Renal Insufficiency and Cancer Medications (IRMA) Study Group</collab>
            </person-group>
            <article-title>Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study.</article-title>
            <source>Cancer</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>1376</fpage>
            <page-range>1376-84</page-range>
            <pub-id pub-id-type="pmid">17634949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortega</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ivy</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Pappo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center.</article-title>
            <source>Cancer</source>
            <year>1997</year>
            <month>Jun</month>
            <day>15</day>
            <volume>79</volume>
            <issue>12</issue>
            <fpage>2435</fpage>
            <page-range>2435-9</page-range>
            <pub-id pub-id-type="pmid">9191535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sulis</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bessmertny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Granowetter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>843</fpage>
            <page-range>843-6</page-range>
            <pub-id pub-id-type="pmid">15591910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ki</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary toxicity after a quick course of combinatorial vincristine, bleomycin, and cisplatin neoadjuvant chemotherapy in cervical cancer.</article-title>
            <source>J Korean Med Sci</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>240</fpage>
            <page-range>240-4</page-range>
            <pub-id pub-id-type="pmid">20119577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starobova</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vetter</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.</article-title>
            <source>Front Mol Neurosci</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>174</fpage>
            <pub-id pub-id-type="pmid">28620280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Csapo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention.</article-title>
            <source>Clujul Med</source>
            <year>2014</year>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-42</page-range>
            <pub-id pub-id-type="pmid">26528012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dorr</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Antidotes to vesicant chemotherapy extravasations.</article-title>
            <source>Blood Rev</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-60</page-range>
            <pub-id pub-id-type="pmid">2182147</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biswal</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study.</article-title>
            <source>Indian J Dermatol</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-46</page-range>
            <pub-id pub-id-type="pmid">29527024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Middleton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Smallwood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine.</article-title>
            <source>Cancer Treat Rep</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <page-range>373-5</page-range>
            <pub-id pub-id-type="pmid">3995509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Malard</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Abecassis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aerts</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alaskar</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Aljurf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bader</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bazarbachi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blaise</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ciceri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corbacioglu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dignan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Masszi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Michallet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>NiChonghaile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pagliuca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Ruutu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Savani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Wallhult</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yakoub-Agha</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Carreras</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>906</fpage>
            <page-range>906-12</page-range>
            <pub-id pub-id-type="pmid">27183098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atkinson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Stover</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Saracino</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rogak</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Matsoukas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Basch</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.</article-title>
            <source>Support Care Cancer</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>3669</fpage>
            <page-range>3669-76</page-range>
            <pub-id pub-id-type="pmid">27260018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aaronson</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Ahmedzai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bullinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cull</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Duez</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Filiberti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Flechtner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fleishman</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>de Haes</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1993</year>
            <month>Mar</month>
            <day>03</day>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>365</fpage>
            <page-range>365-76</page-range>
            <pub-id pub-id-type="pmid">8433390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guzelant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goksel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ozkok</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tasbakan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aysan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bottomley</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.</article-title>
            <source>Eur J Cancer Care (Engl)</source>
            <year>2004</year>
            <month>May</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-44</page-range>
            <pub-id pub-id-type="pmid">15115469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavaletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornblath</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Merkies</surname>
                <given-names>ISJ</given-names>
              </name>
              <name>
                <surname>Postma</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Frigeni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alberti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bruna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Velasco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Argyriou</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kalofonos</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Psimaras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ricard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Briani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalla Torre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lalisang</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Boogerd</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brandsma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koeppen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hense</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kerrigan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schenone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valsecchi</surname>
                <given-names>MG</given-names>
              </name>
              <collab>CI-PeriNomS Group</collab>
              <name>
                <surname>Mazzeo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pace</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pessino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schenone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Toscano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Argyriou</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Frigeni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Piras</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Briani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalla Torre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dominguez Gonzalez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Tomasello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Binda</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brandsma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cortinovis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Psimaras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ricard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cornblath</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lindeck Pozza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vanhoutte</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Lanzani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pastorelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Altavilla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cavaletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Granata</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kalofonos</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Ghignotti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Merkies</surname>
                <given-names>ISJ</given-names>
              </name>
              <name>
                <surname>Bruna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hense</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Heimans</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mattavelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Padua</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bakkers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boogerd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campagnolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cazzaniga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eurelings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leandri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lucchetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Penas Prado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valsecchi</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Piatti</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Alberti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bidoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Plasmati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Velasco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lalisang</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fabbri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dorsey</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Galimberti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kerrigan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koeppen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Postma</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Boogerd</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.</article-title>
            <source>Ann Oncol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>454</fpage>
            <page-range>454-462</page-range>
            <pub-id pub-id-type="pmid">22910842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>EML</given-names>
              </name>
              <name>
                <surname>Zanville</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kanzawa-Lee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Donohoe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loprinzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le-Rademacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.</article-title>
            <source>Support Care Cancer</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>2599</fpage>
            <page-range>2599-2608</page-range>
            <pub-id pub-id-type="pmid">30460399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boccia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Glaspy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aapro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?</article-title>
            <source>Oncologist</source>
            <year>2022</year>
            <month>Aug</month>
            <day>05</day>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>625</fpage>
            <page-range>625-636</page-range>
            <pub-id pub-id-type="pmid">35552754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ichikawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Inamoto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ohshima</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saitoh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaneda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ariga</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>239</fpage>
            <page-range>239-41</page-range>
            <pub-id pub-id-type="pmid">22246157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyle</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Shenfield</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Glutamate ameliorates experimental vincristine neuropathy.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>279</volume>
            <issue>1</issue>
            <fpage>410</fpage>
            <page-range>410-5</page-range>
            <pub-id pub-id-type="pmid">8859020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradfield</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Krischer</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>1004</fpage>
            <page-range>1004-10</page-range>
            <pub-id pub-id-type="pmid">25545757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tofthagen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Visovsky</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hopgood</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management.</article-title>
            <source>Clin J Oncol Nurs</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-44</page-range>
            <pub-id pub-id-type="pmid">23538249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rein</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>[Physical Therapy for Chemotherapy-induced Peripheral Neuropathy in Pediatric Oncology].</article-title>
            <source>Klin Padiatr</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>228</volume>
            <issue>6-07</issue>
            <fpage>313</fpage>
            <page-range>313-318</page-range>
            <pub-id pub-id-type="pmid">27846661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerridge</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Defibrotide Use in Vincristine-induced Hepatic Sinusoidal Obstruction Syndrome.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>539</fpage>
            <page-range>539-541</page-range>
            <pub-id pub-id-type="pmid">28842141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilbar</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Carrington</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-8</page-range>
            <pub-id pub-id-type="pmid">16984750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Forno</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Gozza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silvestro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venturini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosso</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pronzato</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>1994</year>
            <volume>120</volume>
            <issue>8</issue>
            <fpage>505</fpage>
            <page-range>505-6</page-range>
            <pub-id pub-id-type="pmid">8207052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qweider</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gilsbach</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report.</article-title>
            <source>J Neurosurg Spine</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>280</fpage>
            <page-range>280-3</page-range>
            <pub-id pub-id-type="pmid">17355029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hennipman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000f6;kkerink</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ball</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Veerman</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Intrathecal vincristine: 3 fatal cases and a review of the literature.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>11</issue>
            <fpage>816</fpage>
            <page-range>816-9</page-range>
            <pub-id pub-id-type="pmid">19801949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pongudom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chinthammitr</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Inadvertent intrathecal vincristine administration: report of a fatal case despite cerebrospinal fluid lavage and a review of the literature.</article-title>
            <source>J Med Assoc Thai</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>94 Suppl 1</volume>
            <fpage>S258</fpage>
            <page-range>S258-63</page-range>
            <pub-id pub-id-type="pmid">21721457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pierga</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Beuzeboc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorval</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palangie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pouillart</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Favourable outcome after plasmapheresis for vincristine overdose.</article-title>
            <source>Lancet</source>
            <year>1992</year>
            <month>Jul</month>
            <day>18</day>
            <volume>340</volume>
            <issue>8812</issue>
            <fpage>185</fpage>
            <pub-id pub-id-type="pmid">1352603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosmidis</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Bouhoutsou</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Varvoutsi</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Papadatos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stefanidis</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Vlachos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scardoutsou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kostakis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vincristine overdose: experience with 3 patients.</article-title>
            <source>Pediatr Hematol Oncol</source>
            <year>1991</year>
            <season>Apr-Jun</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-8</page-range>
            <pub-id pub-id-type="pmid">1863543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krishnamurthy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhattacharya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lathia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kantroo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Anticancer Medications and Sodium Dysmetabolism.</article-title>
            <source>Eur Endocrinol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-130</page-range>
            <pub-id pub-id-type="pmid">33117443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Groh&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berardi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Runkle</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>SIADH: differential diagnosis and clinical management.</article-title>
            <source>Endocrine</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>311</fpage>
            <page-range>311-319</page-range>
            <pub-id pub-id-type="pmid">27025948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller-Lissner</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Constipation - pathophysiology, diagnostics, treatment].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>144</volume>
            <issue>16</issue>
            <fpage>1145</fpage>
            <page-range>1145-1157</page-range>
            <pub-id pub-id-type="pmid">31416107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sands</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ladas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ndao</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vahdat</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.</article-title>
            <source>Support Care Cancer</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>701</fpage>
            <page-range>701-708</page-range>
            <pub-id pub-id-type="pmid">27830395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy.</article-title>
            <source>Exp Ther Med</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>4017</fpage>
            <page-range>4017-4024</page-range>
            <pub-id pub-id-type="pmid">28105133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-273.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schloss</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Colosimo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Airey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Masci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Linnane</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Vitetta</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).</article-title>
            <source>Support Care Cancer</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>195</fpage>
            <page-range>195-204</page-range>
            <pub-id pub-id-type="pmid">27612466</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
